C-reactive protein in psoriasis: A review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 28, Issue 6, 2014, Pages 700-711

  Beygi, S ^a,b   Lajevardi, V ^a   Abedini, R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b National Elite Foundation   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

CLINICAL EXAMINATION; DISEASE DURATION; DISEASE SEVERITY; HUMAN; MEDICAL LITERATURE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; SYSTEMATIC REVIEW; BLOOD; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX;

EID: 84900501562     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12257     Document Type: Review

References (45)

1. Biljan D, Situm M, Kostovic K, Batinac T, Matisic D,. Acute phase proteins in psoriasis. Coll Antropol 2009; 33: 83-86.
2. Langley RG, Ellis CN,. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004; 51: 563.
3. Po LW,. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
4. Sergeant A, Makrygeorgou A, Chan WC, Thorrat A, Burden D,. C-reactive protein in psoriasis. Br J Dermatol 2008; 158: 417-419.
5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
6. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
7. Boehncke S, Salgo R, Garbaraviciene J, et al,. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
8. Strober B, Teller C, Yamauchi P, et al,. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330.
9. McBride JD, Cooper MA,. A high sensitivity assay for the inflammatory marker C-Reactive protein employing acoustic biosensing. J Nanobiotechnology 2008; 6: 5.
10. Kanelleas A, Liapi C, Katoulis A, et al,. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 2011; 36: 845-850.
11. Lagrand WK, Visser CA, Hermens WT, et al,. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100: 96-102.
12. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH,. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-733.
13. Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I,. Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol 2013; 44: 194-204.
14. Wells G, Shea B, O'connell D, et al,., The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. (last accessed: 1 February 2013).
15. Nisa N, Ahmed Q,. High-sensitivity C-reactive protein in psoriasis. Int J Dermatol 2012; 51: 1393-1394.
16. Coimbra S, Oliveira H, Reis F, et al,. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-796.
17. Chodorowska G, Czelej D, Borowiec M, Pietrzak A, Krasowska D, Kowal M,. Study on activity of interleukin-6, C-reactive protein and alpha-2 macroglobulin in psoriatic patients during the acute clinical stage and remission. Ann Univ Mariae Curie Sklodowska Med 2000; 55: 29-36.
18. Coimbra S, Oliveira H, Reis F, et al,. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol 2010; 11: 423-432.
19. Coimbra S, Oliveira H, Reis F, et al,. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 1386-1394.
20. Romani J, Caixas A, Carrascosa JM, Ribera M, Rigla M, Luelmo J,. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol 2012; 166: 1237-1244.
21. Usta M, Yurdakul S, Aral H, et al,. Vascular endothelial function assessed by a noninvasive ultrasound method and serum asymmetric dimethylarginine concentrations in mild-to-moderate plaque-type psoriatic patients. Clin Biochem 2011; 44: 1080-1084.
22. Yiu KH, Yeung CK, Chan HT, et al,. Increased arterial stiffness in patients with psoriasis is associated with active systemic inflammation. Br J Dermatol 2011; 164: 514-520.
23. Balta I, Balta S, Demirkol S, et al,. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology 2013 [Epub ahead of print].
24. Zhao CT, Yeung CK, Siu CW,. et al. Relationship between parathyroid hormone and subclinical myocardial dysfunction in patients with severe psoriasis, J Eur Acad Dermatol Venereol, 2013 [Epub ahead of print].
25. Serwin AB, Wasowicz W, Chodynicka B,. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition 2006; 22: 860-864.
26. Ctirad A, Lenka B, David P, et al,. Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level. Int J Dermatol 2008; 47: 1011-1014.
27. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, et al,. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol 2012; 22: 337-344.
28. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F,. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928.
29. Coimbra S, Oliveira H, Reis F, et al,. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci 2009; 55: 202-204.
30. Gisondi P, Malerba M, Malara G, et al,. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 2010; 23: 1195-1202.
31. Isha VK, Jain VK, Lal H,. C-reactive protein and uric Acid levels in patients with psoriasis. Indian J Clin Biochem 2011; 26: 309-311.
32. Lora V, Bonaguri C, Gisondi P, et al,. Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab. Immunol Res 2013; 56: 382-389.
33. Laurent MR, Panayi GS, Shepherd P,. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 1981; 40: 66-69.
34. Chandran V, Cook RJ, Edwin J, et al,. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010; 49: 1399-1405.
35. Chandran V, Gladman DD,. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010; 12: 288-294.
36. Bassuk SS, Rifai N, Ridker PM,. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29: 439-493.
37. Chodorowska G, Juszkiewicz-Borowiec M, Czelej D, Wojnowska D, Kowal M,. Activity of Tumor Necrosis Factor-alfa (TNF-alpha) and selected acute phase proteins in plasma of psoriatic patients receiving local treatment. Ann Univ Mariae Curie Sklodowska Med 2001; 56: 165-169.
38. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M,. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol 2004; 18: 180-183.
39. Coimbra S, Oliveira H, Belo L, Figueiredo A, Rocha-Pereira P, Santos-Silva A,. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUVA therapy: a follow-up study. Am J Clin Dermatol 2013; 14: 49-53.
40. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G,. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013; 168: 749-755.
41. Poole CD, Conway P, Currie CJ,. An evaluation of the association between C-reactive protein, the change in C-reactive protein over 1 year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 78-82.
42. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y,. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 2008; 88: 337-340.
43. Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, et al,. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol 2011; 164: 26-32.
44. Ardic I, Kaya MG, Yarlioglues M, et al,. Impaired aortic elastic properties in normotensive patients with psoriasis. Blood Press 2010; 19: 351-358.
45. Warnecke C, Manousaridis I, Herr R, et al,. Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study. Eur J Dermatol 2011; 21: 761-770.